Discussion
tumors, hypersensitivity
TUMORS, HYPERSENSITIVITY
In this study of HER2-positive BCs, our protocol achieved a pCR rate of 53.5% (95% CI: 42.6–64.1%). The low threshold limit was below 45.5% and the We have been interested in nab-PTX from the three available taxanes because it has several advantages compared with other potential drugs. Paclitaxel can improve immunological status by decreasing regulatory T cells (Tregs) and increasing Th1 cytokines, such as IFNγ-and/or IL-2, in vitro and in vivo [TILs were also a predictive factor for the nab-PTX regimen (Fig. Nab-PTX also has a clinical advantage; namely, it shows a very low rate of hypersensitivity because AEs tend to bother patients, which often leads to the termination of the essential treatment. According to previous studies comparing conventional paclitaxel and docetaxel, nab-PXT demonstrated < 1% hypersensitivity of any grade without premedication with steroids [Our multi-institutional prospective phase II trial had some limitations. This was a single-arm study. The small sample size of each subtype may have influenced the results of the primary endpoint. Despite statistical analysis undertaken in a preplanned manner, the multivariable analysis was not performed because our sample size was not large enough.In conclusion, we developed a new chemotherapeutic regimen for HER2-positive BCs. Nab-PTX in combination with T-mab and P-mab is a safe and effective treatment regimen, particularly for HER2-subtype BCs. The microenvironment of tumors, such as TIL, may be a predictive factor for anti-HER2 NAC therapy.
